| [1] |
Roayaie K, Roayaie S. Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time[J]. Clin Liver Dis, 2014, 18(3):603-612.
|
| [2] |
陈规划，郭宇．肝细胞肝癌合并肝静脉、下腔静脉及右心房癌栓的诊断与治疗[J/CD]．中华肝脏外科手术学电子杂志，2013, 2(1):53-55.
|
| [3] |
华学锋，李团结，贾昌昌，等．肝癌相关成纤维细胞对肝细胞肝癌影响的实验研究[J/CD]．中华肝脏外科手术学电子杂志，2013, 2(3):194-199.
|
| [4] |
Peck-Radosavljevic M. Drug therapy for advanced-stage liver cancer[J]. Liver Cancer，2014, 3(2):125-131.
|
| [5] |
Wang F, Liu M, Li X, et al. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells[J]. FEBS Lett, 2013, 587(5):488-495.
|
| [6] |
Xia H, Ooi LL, Hui KM. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma[J]. PLoS One, 2012,7(9):e44206.
|
| [7] |
Xu J, Wu C, Che X, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2):136-142.
|
| [8] |
Guo Y, Liang X, Lu M, et al. Mammalian target of rapamycin as a novel target in the treatment of hepatocellular carcinoma[J]. Hepatogastroenterology, 2009, 57(101):913-918.
|
| [9] |
Ye X, Guo Y, Zhang Q, et al. βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/Cyclin D1 signaling pathway[J]. PloS One, 2013, 8(1):e55615.
|
| [10] |
Wang C, Guo Y, Wang J, et al. The suppressive role of SOX7 in hepatocarcinogenesis[J]. PloS One, 2014, 9(5):e97433.
|
| [11] |
Guo Y, Chen W, Wang W, et al. Simultaneous diagnosis and gene therapy of immuno-rejection in rat allogeneic heart transplantation model using a T-cell-targeted theranostic nanosystem[J]. ACS Nano, 2012, 6(12):10646-10657.
|
| [12] |
Mori M, Triboulet R, Mohseni M, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer[J]. Cell, 2014, 156(5):893-906.
|
| [13] |
Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia[J]. Genome Res, 2010, 20(5):589-599.
|
| [14] |
Xie B, Ding Q, Han H, et al. miRCancer: a microRNA-cancer association database constructed by text mining on literature[J]. Bioinformatics, 2013, 29(5):638-644.
|
| [15] |
Pereira DM, Rodrigues PM, Borralho PM, et al. Delivering the promise of miRNA cancer therapeutics[J]. Drug Discov Today, 2013, 18(5):282-289.
|
| [16] |
Xu CX, Xu M, Tan L, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog[J]. J Biol Chem, 2012, 287(42):34970-34978.
|
| [17] |
Zhang XJ, Ye H, Zeng CW, et al. Dysregulation of miR-15a and miR-214 in human pancreatic cancer[J]. J Hematol Oncol, 2010(3):46.
|
| [18] |
Hong L, Han Y, Lu Q, et al. Drug resistance-related microRNAs in esophageal cancer[J]. Expert Opin Biol Ther, 2012, 12(11):1487-1494.
|
| [19] |
Phatak P, Mansour D, Byrnes K, et al. Overexpression of microRNA 214-3p in esophageal cancer cells enhances sensitivity to chemotherapy-induced apoptosis by targeting CUG-binding protein 1 (CUGBP1) and survivin[J]. Mol Cancer Ther, 2013, 12(11 Suppl):B227.
|
| [20] |
Liu L, Yu X, Guo X, et al. miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2[J]. Mol Med Rep, 2012, 5(3):753-760.
|
| [21] |
Liu C, Kelnar K, Vlassov AV, et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7[J]. Cancer Res, 2012, 72(13):3393-3404.
|
| [22] |
Derfoul A, Juan AH, Difilippantonio MJ, et al. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion, and accumulation of the Polycomb Ezh2 methyltransferase[J]. Carcinogenesis, 2011, 32(11):1607-1614.
|
| [23] |
Liu YQ, Li Y, Qin J, et al. Matrine reduces proliferation of human lung cancer cells by inducing apoptosis and changing miRNA expression profiles[J]. Asian Pac J Cancer Prev, 2014, 15(5):2169-2177.
|
| [24] |
Mezzanzanica D, Canevari S, Cecco LD, et al. miRNA control of apoptotic programs: focus on ovarian cancer[J]. Expert Rev Mol Diagn, 2011, 11(3):277-286.
|